Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + docetaxel
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
The combination of 'anti-PD-1 + docetaxel' in this context refers to a therapeutic regimen consisting of tislelizumab and docetaxel. Tislelizumab is a humanized IgG4-variant monoclonal antibody developed by BeiGene that targets the programmed cell death-1 (PD-1) receptor, thereby blocking the PD-1/PD-L1 immune checkpoint pathway to enhance anti-tumor immune responses. Docetaxel is a cytotoxic taxane that promotes tubulin assembly and stabilizes microtubules, causing cell cycle arrest in the G2/M phase. This combination is being evaluated in the Phase II TRACE trial (NCT06469060) as part of a neoadjuvant immunochemotherapy strategy for patients with resectable adenocarcinoma of the esophagogastric junction (AEG), where it is administered alongside oxaliplatin and capecitabine.
- Brand names
- Tevimbra + Taxotere
- Other names
- anti-PD-1 + docetaxeltislelizumab plus docetaxel
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)PDCD1 (Programmed cell death protein 1 receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tislelizumab + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + docetaxel.